We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10).
- Authors
Lee, Soohyeon; Im, Seock-Ah; Kim, Gun Min; Jung, Kyung Hae; Kang, Seok Yun; Park, In Hae; Kim, Jee Hyun; Lee, Kyoung Eun; Ahn, Hee Kyung; Lee, Moon Hee; Kim, Hee-Jun; Kim, Han Jo; Lee, Jong In; Koh, Su-Jin; Park, Yeon Hee
- Abstract
Simple Summary: We reported that palbociclib plus exemestane with ovarian function suppression (with leuprolide) led to significantly longer median progression-free survival compared with capecitabine in premenopausal metastatic breast cancer patients. We also evaluated differences of patient report outcomes (PROs) between palbociclib plus endocrine therapy (ET) and capecitabine as upfront therapy in this study population. All the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) were maintained from baseline to the end of treatment within each treatment arm. Patients with palbociclib plus ET arm experienced delay in time to deterioration of physical functioning, nausea and vomiting, and diarrhea. There was a trend for worsening of insomnia in the palbociclib plus endocrine therapy (ET) arm and appetite loss in the capecitabine arm. Patients with palbociclib plus ET had significant overall improvement of quality of life and significant delay in time to deterioration without compromising treatment efficacy. In the era of CDK4/6 inhibitors in hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, few trials have been specifically studied to compare quality of life between palbociclib plus endocrine therapy (ET) and cytotoxic chemotherapy exclusively in premenopausal women. We aimed to evaluate differences of patient report outcomes (PROs) between palbociclib plus ET and capecitabine. PROs were assessed using EORTC QLQ-C30 at baseline, every 6 weeks, and the end of treatment. All EORTC QLQ-30 scores were maintained from baseline to the end of treatment. Patients treated palbociclib plus ET arm experienced delay in time-to-deterioration of physical functioning (HR = 0.58, 95% CI, 0.36 to 0.84, p = 0.0058), nausea and vomiting (HR = 0.48; 95% CI, 0.32 to 0.73, p = 0.0005), and diarrhea (HR = 0.42; 95% CI, 0.27 to 0.65, p = 0.001). There was a numeric trend for worsening of insomnia (HR = 1.43; 95% CI, 0.96 to 2.16, p = 0.079) and favoring of appetite loss (HR = 0.69, 95% CI, 0.44 to 1.07, p = 0.09) in the palbociclib plus ET arm. Premenopausal patients with palbociclib plus ET maintained QoL without compromising treatment efficacy.
- Subjects
THERAPEUTIC use of antineoplastic agents; BREAST tumors; CONFIDENCE intervals; DRUG side effects; LIFE skills; LONGITUDINAL method; METASTASIS; HEALTH outcome assessment; QUALITY of life; QUESTIONNAIRES; PERIMENOPAUSE; RANDOMIZED controlled trials; PROTEIN kinase inhibitors; DESCRIPTIVE statistics; EXEMESTANE; EVALUATION
- Publication
Cancers, 2020, Vol 12, Issue 11, p3265
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers12113265